American acne & rosacea society rosacea medical management guidelines

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages 531-533

  Del Rosso, James Q ^a   Baldwin, Hilary ^a   Webster, Guy ^a  

^a American Acne and Rosacea Society (AARS)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT; TOPICAL ANTIINFECTIVE AGENT;

ARTICLE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; QUALITY OF LIFE; ROSACEA;

ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DERMATOLOGIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; ROSACEA;

EID: 47249164055     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Crawford GH, Pelle MT, James WD. Rosacea I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004; 51:327-341. (Pubitemid 39178655)
2. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912. (Pubitemid 38685771)
3. Dahl M. Pathogenesis of rosacea. Adv Dermatol. 2001;17:29-45.
4. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206. (Pubitemid 32927782)
5. Millikan LE. Rosacea as an inflammatory disorder: a unifying theory? Cutis. 2004;73 (suppl):1-5.
6. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100. (Pubitemid 44433118)
7. National Rosacea Society. What is rosacea? Available at: www.rosacea.org. Accessed July 10, 2007.
8. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
9. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Exp Opin Pharmacother. 2004;5:5-13. (Pubitemid 38072714)
10. Del Rosso JQ. A status report on medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275. (Pubitemid 41750798)
11. Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004;74 (suppl 3):21-27. (Pubitemid 39330114)
12. McClellan KJ, Noble S. Topical metronidazole: a review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
13. Wolf JE, Kerrouche N, Arsonnaud S. Efficacy and safety of oncedaily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77 (suppl):3-11. (Pubitemid 43723532)
14. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid 15% gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
15. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid and 0.75% metronidazole gel in the topical management of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
16. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156:728-738.
17. El Sayed F, Ammoury A, Dhaybi R, et al. Rosaceaform eruption to pimecrolimus. J Am Acad Dermatol. 2006;54:548-550.
18. Bamford JT, Elliot BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol. 2004;50:107-108. (Pubitemid 38095664)
19. Antille C, Saurat JH, Lubbe J. Induction of rosaceaform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-460. (Pubitemid 38469249)
20. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73 (suppl):11-17. (Pubitemid 38843992)
21. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/ clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-387. (Pubitemid 38714606)
22. Fortsinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and permethrin cream. J Am Acad Dermatol. 1999;41:775-777. (Pubitemid 29514037)
23. Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75% metronidazole gel in acne rosacea. Cutis. 1995;56:177-179.
24. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized, phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;65:791-802. (Pubitemid 46561002)
25. Package Insert. Oracea, Collagenex Pharmaceuticals, Physicians Desk Reference, 2007.
26. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. SkinMed. 2003;2:234-245.
27. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial- dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464. (Pubitemid 36427610)
28. Weinberg J. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75 (suppl 4):6-11. (Pubitemid 40627619)
29. Webster GF, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatologic Clinics. 2007;25:133-135. (Pubitemid 46566395)
30. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54:258-265. (Pubitemid 43144395)
31. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatologic Clinics. 2007;25:127-132. (Pubitemid 46566394)
32. Bikowski JB, Goldman MP. Rosacea: where are we now? J Drugs Dermatol. 2004;3:251-261.
33. Del Rosso JQ. Introduction. scientific panel on antibiotic use in dermatology. Cutis. 2007;79 (suppl):6-8.
34. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79 (suppl):9-25.
35. Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol. 1982;6 (suppl):766-785.
36. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-663. (Pubitemid 17210593)
37. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141. (Pubitemid 38932283)
38. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17 (suppl):26-34.
39. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004; 74 (suppl): 28-34.
40. Del Rosso JQ. The role of skin care and maintaining proper barrier function in the management of rosacea. J Cosmet Dermatol. 2007; 20:485-490. (Pubitemid 47338972)
41. Draelos ZD, Green BA, Edison BL. An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. J Cosmet Dermatol. 2006;5:23-29.